EE40 Identifying and Quantifying Elements of Value for Nivolumab and Ipilimumab in First-Line Non-Small Cell Lung Cancer

Abstract

Cost-effectiveness analyses are often used by health technology appraisal agencies to inform reimbursement decisions for new therapies. These evaluations, however, are often performed adopting a payer’s perspective that does not include important elements of value that treatments may generate (e.g., increased productivity, reduced caregiving costs, patients’ hope, option value, or insurance value). There is currently limited evidence quantifying condition-specific novel value elements.